

## Regulated Drug Rule

### 1.0 Authority

This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety.

### 2.0 Purpose

This rule designates drugs and other chemical substances that are controlled or illegal because they are potentially fatal or harmful for human consumption. Some of the designated drugs are prescribed drugs dispensed by a professional licensed to prescribe or dispense them. The rule restricts the possession of certain prescribed drugs above a specified quantity.

### 3.0 Definitions

- 3.1** “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures.
- 3.2** “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for 18 V.S.A. § 4234.
- 3.3** “Depressant drug” means any drug which contains any substances, its salt, optical isomers, salts of its optical isomers, derivatives or analogs of substances, designated in Section 5.0 of this rule as habit forming because of its effect on the central nervous system or as having a serious potential for abuse arising out of its effect on the central nervous system.
- 3.4** “Derivative” shall mean a compound that can be obtained from a parent compound as a result of a chemical reaction which replaces one atom/functional group with a different one.
- 3.5** “Hallucinogenic Drug” means those specified in Section 7 of this rule including stramonium, mescaline or peyote, lysergic acid diethylamide, and psilocybin, and all synthetic equivalents of chemicals contained in resinous extractives of Cannabis

sativa, or any salts or derivatives or compounds of any preparations or mixtures thereof, and any other substance having a hallucinogenic effect in the regulations adopted by the Board of Health under 18 V.S.A. § 4202.

- 3.6** “Narcotic drug” means those specified in Section 6.0 of this rule including opium, coca leaves, pethidine (isonipecaine, meperidine), and opiates or their compound, manufacture, salt, alkaloid, or derivative, and every substance neither chemically nor physically distinguishable from them, and preparations containing such drugs or their derivatives, by whatever trade name identified and whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, as the same are so designated in the regulations adopted by the Board of Health under 18 V.S.A. § 4202.
- 3.7** “Regulated drug” means a narcotic drug, a depressant or stimulant drug, a hallucinogenic drug, Ecstasy, marijuana, or methamphetamine whose possession or use is regulated by law.
- 3.8** “Stimulant drug” means any drug which contains any quality of a substance, its salt, optical isomers, salts of it optical isomers, derivatives or analogs of substances, designated in Section 4.0 of this rule as habit forming because of its effect on the central nervous system or as having a serious potential for abuse arising out of its effect on the central nervous system.

#### **4.0 Stimulant Drugs; Trade or Chemical Name**

- 2-AI; 2-Aminoindane
- 2-diphenylmethylpyrrolidine; 2-benzylhydrilpyrrolidine; OR (S)-(-)-2-(diphenylmethyl)pyrrolidine; OR (S)-2-diphenylmethylpyrrolidine; OR (2S)-2-benzylhydrilpyrrolidine; OR (2S)diphenylmethylpyrrolidine
- 2-DPMP; desoxypipradrol; OR diphenylprolinol; OR 2-diphenylmethylpiperidine
- 2-FMA; 2-fluoromethamphetamine
- 2-FMC; 2-fluoromethcathinone
- 2-methylmethcathinone; 2-MMC; 2-Methyl MC
- 3-FMC; 3-fluoromethcathinone
- 3,4-DMMC; 3,4-dimethylmethcathinone

- 3, 4 methylenedioxy-methamphetamine (MDMA)
- 3,4-methylenedioxy-N-methylcathinone (methydone)
- 3,4-methylenedioxypropylvalerone (MPDV)
- 4-bromomethylcathinone; 4-BMC
- 4-chloromethylcathinone; 4-CMC; Clephedrone
- 4-EMC; 4-ethylmethylcathinone; OR 4-ethyl-methylcathinone
- 4FA, PFA; 4-fluoroamphetamine; parafluoroamphetamine
- 4-FMA; 4-fluoromethamphetamine
- 4-FMC, Flephedrone; 4-fluoromethylcathinone
- 4-FPP, pFPP; 4-fluorophenylpiperazine
- 4-MBC, Benzedrone; ( $\pm$ )-1-(4-methylphenyl)-2-(benzylamino)propan-1-one; OR 4-methyl- N-benzylcathinone; OR N-benzyl-4-methylcathinone; OR 1-(4-methylphenyl)-2- benzylaminopropan-1-one
- 4-MEC; 4-methyl-N-ethylcathinone; OR 4-methylethylcathinone; OR para-methyl-N-ethylcathinone; OR para-methylethylcathinone; OR 4-methyl-ethylcathinone
- 4-MPD; 4-Methyl-Pentedrone
- 5-IAI; 5-Iodo-2-Aminoindane
- 5-ME, 5-methyl-ethylone
- a-ethylaminopentiophenone
- a-PBP, alpha-PBP; alpha-Pyrrolidinobutiophenone; OR a-Pyrrolidinobutiophenone; OR (RS)1-phenyl-2-(1-pyrrolidinyl)-1-pentanone
- a-PPP, alpha-PPP; alpha-pyrrolidinopropiophenone; OR a-pyrrolidinopropiophenone
- a-PVP, alpha-PVP; alpha-Pyrrolidinopentiophenone; OR a-Pyrrolidinopentiophenone; OR 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone; OR alpha-pyrrolidinovalerophenone; OR a-pyrrolidinovalerophenone
- Amphetamine
- Benzphetamine
- bk-2C-B; bk-4 Bromo-2,5-dimethoxyphenethylamine

- BZP; benzylpiperazine; OR N-benzylpiperazine
- Buphedrone; a-methylamino-butyrophenone; OR 2-(methylamino)-1-phenylbutan-1-one; OR alpha-methylamino-butyrophenone
- Butylone, bk-MBDB; beta-Keto-N-methylbenzodioxolylpropylamine; OR beta-Keto-N- methyl-3,4-benzodioxolybutanamine
- Cathine
- Cathinone
- Cathinone derivatives: Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways: (i) by substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents; (ii) by substitution at the 3-position with an alkyl substituent; (iii) by substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.
- Chlorphentermine
- Clortermine
- D2PM; diphenyl-2-pyrrolidinyl-methanol ; diphenyl prolinol
- DBP; DBZP; 1,4-dibenzylpiperazine
- Diethylpropion
- Dimethocaine; (3-diethylamino-2,2-dimethylpropyl)-4-aminobenzoate
- Ethcathinone; 2-ethylamino-1-phenyl-propan-1-one
- Ethylone; 3,4-methylenedioxy-N-ethylcathinone; OR 3,4-methylenedioxyethylcathinone; OR 3,4-methylenedioxy-ethylcathinone; OR 3,4-methylenedioxyethcathinone
- Eutylone; beta-Keto-Ethylbenziodioxolylbutanamine HMMC; 3-methoxymethcathinone; 3-MeOMC
- Gamma butyrolactone
- Gamma hydroxybuturic
- M11; dimethylone
- MaPPP, 4-MePPP; 4-methyl-alpha-pyrrolidinopropiophenone; OR 4-methyl-a-pyrrolidinopropiophenone; OR methylpyrrolidinopropiophenone

- MBPV; 5-DBFPN; 1-(2,3-dihydrobenzofuran-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one
- MBZP; 1-methyl-4-benzylpiperazine
- mCPP; 1-(3-chlorophenyl)piperazine
- MDAI; methylenedioxy-aminoindane; OR 5,6-methylenedioxy-2-aminoindane
- MDAT; 6,7-methylenedioxy-2-aminotetralin
- MDPBP; 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone; OR 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone
- MDPPP; 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone; OR (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone; OR 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone
- Methiopropamine, MPA
- MeOPP; 1-(4-methoxyphenyl)piperazine
- Mitragynine
- MOPPP; 4-methoxy-alpha-pyrrolidinopropiophenone; OR 4-methoxy-alpha-pyrrolidinopropiophenone
- MPBP; 4-methyl-alpha-pyrrolidinobutyrophenone; OR 4-methyl-alpha-pyrrolidinobutyrophenone; OR 4-methyl-alpha-pyrrolidinobutiophenone; OR 4-methyl-alpha-pyrrolidinobutiophenone; 4-MPBP
- Mazindol
- Mephedrone (4-methyl methtramadolcathinone)
- Mephtetramine; MTA
- Methamphetamine
- Methcathinone
- Metamfepramone; N,N-dimethylcathinone
- Methedrone, Bk-PMMA, PMMC; para-methoxymethcathinone; OR 4-methoxymethcathinone; OR methoxyphedrine; OR (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one
- Methylphenidate
- MT-45; IC-6; NSC 299236; 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine
- NRG-1; Naphyrone, naphthylpyrovalerone;

- NRG-2
- NM2AI; NM-2AI; N-Methyl-2-Aminoindane
- Pemoline (including organometallic complexes and chelates thereof)
- Pentedrone; a-methylamino-Valerophenone; OR 2-(methylamino)-1-phenyl-1-pentanone; OR 2-methylamino-1-phenyl-1-pentanone
- Pentylone; beta-Keto-N-methylbenzodioxolypentanamine; OR beta-keto-ethylbenzodioxolypentanamine
- Phendimetrazine
- Phenmetrazine
- Phentermine
- Pyrovalerone; (Valerophenone, Thymergix, Centroton)
- TFMPP; 1-[3-(trifluoromethyl)phenyl]piperazine

## 5.0 Depressant Drugs; Trade or chemical Name

- Alprazolam
- Barbituric acid and its derivatives
- Chloral betaine
- Chloral Hydrate
- Chlorexadol
- Clonazepam
- Clorazepate
- Clordiazepoxide
- Diazepam
- Ethchlorvynol
- Ethinamate
- Fenfluramine

- Flurazepam
- Glutethimide
- Ketamine
- Lorazepam
- Lysergic acid
- Lysergic acid amide
- Mebutamate
- Mecloqualone
- Meprobamate
- Methaqualone
- Methyprylon
- Oxazepam
- Paraldehyde
- Petrichloral
- Phenazepam; BD 98; Fenazepam
- Phencyclidine
- Sulfondiethylmethane
- Sulfonethylmethane
- Sulfonmethane
- Temazepam
- Triazolam

## **6.0 Narcotic Drugs; Trace or Chemical Name**

- Acetorphine
- Acetyldihydrocodeine

- Acetyl-fentanyl
- Acetylmethadol
- Allylprodine
- Alphacetylmethadol
- Alphameprodine
- Alphamethadol
- Alphaprodine
- Anileridine
- Benzethidine
- Benzylmorphine
- Betacetylmethadol
- Betameprodine
- Betamethadol
- Betaprodine
- Bezitramide
- Buprenorphine
- Clonitazene
- Coca leaves and any salt, compound derivative, or preparation of coca leaves, and any salt compound derivative or preparation thereof which is chemically equivalent or identical regardless of optical isomers with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecognine
- Cocaine
- Codeine
- Codeine methylbromide
- Codeine-N-Oxide

Chapter 8 Alcohol and Drug Abuse  
Subchapter 9

- Cyprenorphine
- Desomorphine
- Dextromoramide
- Diampromide
- Dichloropane, RTI-111, O-401; methyl (1R,2S,3S,5S)-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane-2-carboxylate
- Diethylthiambutene
- Difenoxin
- Dihydrocodeine
- Dihydromorphine
- Dimenoxadol
- Dimepheptanol
- Dimethylthiambutene
- Dioxaphetyl butyrate
- Diphenoxylate
- Dipipanone
- Drotebanol
- Ethylmethylthiambutene
- Ethylmorphine
- Etonitazene
- Etorphine
- Etoxadine
- Fentanyl
- Furethidine
- Heroin

Chapter 8 Alcohol and Drug Abuse  
Subchapter 9

- Hydrocodone
- Hydromorphenol
- Hydromorphone
- Hydroxypethidine
- Isomethadone
- Ketobemidone
- Levomethorphan
- Levomoramide
- Levophenacymorphan
- Levorphanol
- Metazocine
- Methadone
- Methadone-Intermediate 4-cyano-2-dimethylamino-4, 4-diphenyl butane
- Methyldesorphine
- Methyldihydromorphine
- Methopholine; 1-[2-(4-chlorophenyl)ethyl]-6,7-dimethoxy-2-methyl-1,2,3,4 tetrahydroisoquinoline
- Metopon
- Moramide-Intermediate, 2- methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid
- Morpheridine
- Morphine
- Morphine methylbromide
- Morphine methylsulfonate
- Morphine-N-Oxide
- Myrophine

- Nicocodeine
- Nicomorphine
- Noracymethadol
- Norlevorphanol
- Normethadone
- Normorphine
- Norpipanone
- o-desmethyltramadol; 3-[2-(1-Amino-1-methylethyl)-1-hydroxycyclohexyl]phenol
- Opium poppy and poppy straw
- Raw opium
- Opium extracts
- Oxycodone
- Oxymorphone
- Pentazocine (Hcl and ASA)
- Pethidine
- Pethidine-Intermediate- A, 4-cyano-1-methyl-4-phenylpiperidine
- Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate
- Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid
- Phenadoxone
- Phenampromide
- Phenazocine
- Phenomorphan
- Phenoperidine
- Pholcodine
- Piminodine

- Piritramide
- Proheptazine
- Properidine
- Propiram
- Propoxyphene
- Racemethorphan
- Racemoramide
- Racemorphan
- Thebacon
- Thebaine
- Tilidine
- Tramadol
- Trimeperidine

Any compound specified in 18 VSA 4215a(b) shall be excluded for purposes of this regulation.

**7.0 Hallucinogenic Drugs; Synthetic Cannabinoids; Tryptamines; Cannabinimimetics; Mescaline Analogs; Dissociatives; Trade or Chemical Name**

- 1-(4-methoxybenzoyl)-4-methylpiperazine;MEXP;Methoxypiperamide
- 2,5-dimethoxyamphetamine; 2,5-dimethoxy-a-methylphenethylamin 2,5 DMA
- 2-MeO-ketamine; methoxyketamine
- 2C-B; 4-bromo-2,5-dimethoxy-benzeneethanamine, monohydrochloride
- 2C-C; 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine
- 2C-D; 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine
- 2C-E; 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine
- 2C-H; 2-(2,5-Dimethoxyphenyl)ethanamine

- 2C-I; 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine
- 2C-N; 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine
- 2C-P; 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine
- 2C-T-2; 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
- 2C-T-4; 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
- 2C-T-7; 2,5-dimethoxy-4-(propylthio)-benzeneethanamine, monohydrochloride
- 2C-TFM-NBOMe; 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
- 2CBCB-NBOMe; N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
- 2CBFly-NBOMe; N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane
- 3,4,5-trimethoxy amphetamine
- 3,4-methylenedioxy amphetamine
- 3-HO-PCE; 3-[1-(ethylamino)cyclohexyl]phenol
- 3-HO-PCP
- 3-Methoxyphencyclidine; 3-MeO-PCP; 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine
- 4-AcO-DET; 3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate
- 4-AcO-DMT; 3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl acetate
- 4-AcO-DPT
- 4-AcO-MET; 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl acetate
- 4-bromo-2, 5-dimethoxyamphetamine; DOB; bromo-DMA
- 4-HO-MET; 3-(2-(ethyl(methyl)amino)ethyl)-1H-indol-4-ol
- 4-HO-MIPT; 3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol; 4-hydroxy-MIPT
- 4-HO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydroxyindole
- 4-HO-MPT; 3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol

- 4-MeO-AET
- 4-MeO-MIPT
- 4-MeO-PCP; 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine; 4-Methoxyphencyclidine (methoxydine)
- 4-methoxyamphetamine; 4-methoxy- $\alpha$ -methylphenethylamine paramethoxyamphetamine: PMA
- 4-methyl-2, 5-dimethoxyamphetamine; 4-methyl-2, 5-dimethoxy- $\alpha$ -ethylphenethylamine; “DOM”; and “STP.”
- 4-methyl-AET
- 5-APB; 5-(2-aminopropyl)benzofuran
- 5-EAPB; 5-(2-Ethylaminopropyl)Benzofuran
- 5F-AMB; 5-fluoro AMP
- 5F-ADBICA; 5-fluoro ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide
- 5F-AKB48; AKB48 N-(5-fluoropentyl) analog; 5f-APINACA; APINACA 5-fluoropentyl analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
- 5F-MN-018; 5-fluoro MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide
- 5F-MN24; 5-fluoro NNEI; 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide
- 5F-SDB-005; naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate
- 5F-THJ-2201; (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone
- 5FAB-FUBINACA
- 5FAB-PINACA; AB-PINACA 5 fluoro analog; (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
- 5FPB22; 5-fluoro PB-22; 5-fluoro QUPIC; 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid
- 5FSDB-006; 5-fluoro SDB-006; N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
- 5-IT; 5-(2-aminopropyl)indole
- 5-MAPB; 5-(2-Methylaminopropyl) Benzofuran
- 5-MeO-AMT; 1-(5-methoxy-1H-indol-3-yl)propan-2-amine

- 5-MeO-DALT; N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine; 5-MED
- 5-MeO-DET; N,N-Dethyl-5-Methoxytryptamine
- 5-MeO-DIPT; 3-[2-(Diisopropylamino)ethyl]-5-methoxyindole
- 5-MeO-DMT; 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine
- 5-MeO-DPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1-amine
- 5-MeO-MDA; 5-methoxy-3, 4-methylenedioxy amphetamine
- 5-MeO-MIPT; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
- 5-methoxy-3,4-methylenedioxy amphetamine
- 5-MeO-MPMI; (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole
- 5F-UR-144; (5-fluoropentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; XLR11
- 6-APB; 6-(2-aminopropyl)benzofuran
- 7-hydroxymitragynine; ( $\alpha$ E,2S,3S,7aS,12bS)-3-Ethyl-1,2,3,4,6,7,7a,12b-octahydro-7a-hydroxy-8-methoxy- $\alpha$ -(methoxymethylene)indolo[2,3-a]quinolizine-2-acetic acid methyl ester
- 25B-NBOMe; NBOMe-2C-B; BOM 2-CB; Cimbi-36; 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
- 25C-NBOMe ; 2C-C-NBOMe; NBOMe-2C-C; Cimbi-82; 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
- 25I-NBF; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethanamine
- 25I-NBMD; NBMD-2C-I; Cimbi-29; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine
- 25I-NBOH; 2-((2-(4-iodo-2,5-dimethoxyphenyl)ethylamino)methyl)phenol
- 25I-NBOMe; 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
- A1 dodeca-2E, 4E, 8Z, 10Z – tetraenoic acid isobutyl amide
- A2 dodeca-2E, 4E, dienoic acid idobutylamide
- A796,260; 1-(2-morpholin-4-ylethyl)-1H-indol-3-yl]-(2,2,3,3 tetramethylcyclopropyl) methanone
- A-834,735; 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone

- A-836,339; N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide
- AB-001; 1-pentyl-3-(1-adamantoyl) indole
- AB-034; [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone
- AB-CHMINACA; N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
- AB-PINACA; (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide
- ACEA; N-(2-chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide
- ACPA; N-cyclopropyl-5Z,8Z,11Z,14Z-eicosatetraenamide
- ADBICA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide
- AH-7921; 3,4-dichloro-N-[(1dimethylamino)cyclohexylmethyl]benzamide
- AKB-48; N-adamantyl-1-pentylindazole-3-carboxamide (APINACA)
- AL-LAD; 6-allyl-6-nor-LSD; 6-Allyl-6-nor-lysergic acid diethylamide
- AM630; Iodopravadoline; [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone
- AM-679; 1-pentyl-3-(2-iodobenzoyl)indole
- AM-694; 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; OR 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone
- AM-1220; (R)-1-(((1-methylpiperidin-2-yl)methyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone; OR 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole; OR 1-[(N-methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole
- AM-1241; 1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole
- AM-1248; 1-[(N-methylpiperidin-2-yl)methyl]-3-(adamant-1-oyl)indole
- AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole
- AM-2233; 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole
- AM-4113
- AMT; a-methyltryptamine

- ASDB-FUB-187 BAY 38-7271; (-)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1- sulfonate
- Bufotenine; 3-(b-dimethylaminoethyl) 5-hydroxyindole; 3-(2-di-methylamineethyl) -5- indolol;N, N-dimethylserotonin; 5-hydroxy-N-dimethyltryptamine; mappine.
- CB-13, SAB-378; Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone
- CP47,497
- CP 47,497 homologues; Known as the C6, C7, C8 or C9 homologues and also the dimethylhexyl, dimethylheptyl; dimethyloctyl or dimethylnonyl homologues
- CP 50,556-1, Levonantradol; 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate; OR [(6S,6aR,9R, 10aR)-9- hydroxy-6-methyl-3-[(2R)-5-ph enylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a- octahydrophenanthridin-1-yl] acetate; OR [9-hydroxy-6-methyl-3-[5-phenylpentan-2- yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate
- CP 55,940; 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2- methyloctan-2-yl)phenol
- cannabicyclohexanol
- Cannabimimetic Agents means, collectively, any chemical that is a cannabinoid receptor type 1 (CB1) or cannabinoid receptor type 2 (CB2) agonist, or any salts, isomers, derivatives, or analogs of these chemicals. Structural classes include but are not limited to: (a) 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent. (b) 3-(1-naphthoyl)indole or 3-(1-naphthyl)indole with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent. (c) 3-(1-naphthoyl)pyrrole with substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent. (d) 1-(1-naphthylmethyl)indene with substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.(e) 3-phenylacetylindole or 3-benzoylindole with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. (f) indole- (2,2,3,3-tetramethylcyclopropyl)methanone, with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. (g) N- adamantyl-indole-3-carboxamide, with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent. (h) (1,3-thiazol-2-ylidene)-2,2,3,3- tetramethylcyclopropane-1-carboxamide, with substitution to any extent at any position of the thiazolylidine ring.
- DET; Diethyltryptamine; N, N-Diethyltryptamine
- Dextrorphan

- DIPT; Diisopropyltryptamine
- DMT; Dimethyltryptamine
- DPT; N,N,-dipropyltryptamine
- EAM-2201; JWH-210 N-(5 fluoropentyl) analog; (4-ethyl-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]-methanone
- EG-018; naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone
- Ethyl-ketamine; 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone
- FDU-PB-22; naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate
- FAB-144; (1-(5-fluoropentyl)-1H-indazol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
- F-UPB-22
- FUB-AKB48; AKB48 N-(4-fluorobenzyl) analog; N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide
- FUB-PB22; FUB-PB-22; ; quinolin-8-yl-1-(4-fluorobenzyl)-1H-indole-3-carboxylate
- FUBIMINA; AM2201 Benzimidazole analog; BIM-2201, FTHJ; (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
- HDMP-28; Methylnaphthidate
- HU-210; (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR 1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol
- HU-211, Dexanabinol; (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; OR (6aS, 10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
- HU-243; 3-dimethylheptyl-11-hydroxyhexahydrocannabinol; canbisol, nabidrox
- HU-308; [(91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol
- HU-331; 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione
- Ibogaine; 7-Ethyl-6, 6a,7,8,9,10,12, 3-octahydro-2-methoxy-6, 9-methano-5H-pyrido (1', 2': 1,2-azepine 4, 5-b) indole; tabernanthe iboga

- JTE-907; N-(benzol[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2- dihydroquinoline-3-carboxamide
- JWH-007; 1-pentyl-2-methyl-3-(1-naphthoyl)indole
- JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone; OR 1-propyl-2- methyl-3-(1-naphthoyl)indole; OR (2-methyl-1-propyl-1H-indol-3-yl)-1- naphthalenyl-methanone
- JWH-016; (1-butyl-2-methyl-1H-indol-3-yl)-1-naphthalenyl-methanone)
- JWH-018; AM-678; Naphthalen-1-yl-(1-pentylindol-3-yl)methanone
- JWH-019; naphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-hexyl-3-(1- naphthoyl)indole; OR 1-hexyl-3-(naphthoyl)indole; OR 1-hexyl-3-(naphthalen-1- oyl)indole
- JWH-022; 1-naphthalenyl[1-(4-penten-1-yl)-1H-indol-3-yl]-methanone
- JWH-030; naphthalen-1-yl-(1-pentylpyrrol- 3-yl)methanone
- JWH-073; naphthalen-1-yl-(1-butylindol-3-yl)methanone
- JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4- methoxy-1-naphthoyl)indole; OR 4-methoxynaphthalen-1-yl-(1-pentylindole-3-yl) methanone; OR 1-pentyl-3-[1-(4-methoxynaphthoy)]indole
- JWH-098; 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; OR 4-methoxynaphthalen- 1-yl-(1-pentyl-2-methylindol-3-yl)methanone
- JWH-122; 1-pentyl-3-(4-methyl-1-naphthoyl)indole; OR (4-methyl-1-naphthalenyl)(1- pentyl-1H-indol-3-yl)-methanone
- JWH-147; (1-hexyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenyl-methanone
- JWH-164; 1-pentyl-3-(7-methoxy-1-naphthoyl)indole; OR 7-methoxynaphthalen-1-yl-(1- pentylindol-3-yl)methanone
- JWH-167; 1-pentyl-3-(phenylacetyl)indole
- JWH-175; 3-(naphthalen-1-ylmethyl)-1-pentyl-1H-indole; OR 1-Pentyl-1H-indol-3-yl-(1- naphthyl)methane
- JWH-176; E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane
- JWH-184; 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane
- JWH-199
- JWH-200; WIN 55,225; (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone

- JWH-201; 1-pentyl-3-(4-methoxyphenylacetyl)indole; OR 1-pentyl-3-(4-methoxyphenylacetyl)indole
- JWH-203; 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-chlorophenylacetyl)indole
- JWH-210; 4-ethyl-naphthalen-1-yl-(1-pentylindol-3-yl)methanone; OR 1-pentyl-3-(4-ethyl-1-naphthoyl)indole
- JWH-250; 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone; OR 1-pentyl-3-(2-methoxyphenylacetyl)indole; OR 1-pentyl-3-(methoxyphenylacetyl)indole; OR 1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone
- JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone; OR 1-pentyl-3-(2-methylphenylacetyl)indole
- JWH-302; 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone
- JWH-307; (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone
- JWH-370; [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone
- JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole
- L-759,633; 3-(1,1-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-methoxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
- L-759,656
- Lysergic acid
- Lysergic acid amide
- Lysergic acid dimethylamide
- LSZ; Lysergic acid 2,4-dimethylazetidide, Diazedine, Lambda, LA-SS-AzLysergic acid diethylamide
- MAM-2201; 4-methyl-1-naphthalenyl(1-fluoropentyl-1H-indol-3-yl)methanone
- MIPT; N-isopropyl-N-methyltryptamine
- MA-CHMINICA; AMB N-METHYLCYCLOHEXYL ANALOG, AB-CHMINACA, MAB-AB-CHMINACA; methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-valinate
- MDMB-CHMINICA; (S)-MDMB-CHMINACA; N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester

Chapter 8 Alcohol and Drug Abuse  
Subchapter 9

- Mepirapim; JWH-018-4(methylpiperazine); (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl)methanone, monohydrochloride
- Mescaline
- Methoxetamine (MXE); 3-MeO-2-Oxo-PCE; (RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone
- MMB-2201; I-AMB; methyl (1-(5-fluoropentyl)-1H-indole-3-carbonyl)-L-valinate
- MMB-CHMINACA; (2S)-methyl-2-(1-(cyclohexylmethyl)-1 H-indol-3-ylcarbonylamino)-3,3-dimethylbutanoate
- MN-18; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide
- MN-24; NNEI; N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; AM-6527
- N-ethyl-3 piperidyl benzilate
- N-methyl-3-piperidyl benzilate
- NM2201
- Peyote
- Psilocybin
- Psilocin; 4-OH-DMT
- RCS-4, SR-19; [(4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone]; OR 1-pentyl-3-[(4-methoxy)-benzoyl]indole; OR 1-pentyl-3-(4-methoxybenzoyl)indole; OR (4- methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone
- RCS-8, SR-18; 1-(2-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-methoxyphenylethanone); OR 1-[2-(2-cyclohexylethyl)-1H-indol-3-yl]-2-methoxyphenylethanone; OR 1-(2- cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
- STS-135; N-adamantyl-1-pentylindazole-3-carboxamide
- Salvia divinorum
- Salvinorin A, Active ingredient of salvia plant
- SDB-005; naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate
- SR 144528; 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide
- STS-144; (1-(5-fluoropentyl)-1H-indol-3-yl)(pyridin-3-yl)methanone

- Stramonium
- THJ-018; JWH-018 Indazole analog; 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone
- THJ-2201; Fluoropentyl JWH-018 Indazole, AM2201 indazole analog, 5-Fluoro
- Tetrahydrocannabinols (Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numeric designation of atomic position are covered).
- Thiophene Analog of Phencyclidine; 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thyneyl Analog of Phencyclidine; TPCP
- UR-144; (1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone
- URB-597; [3-(3-carbamoylphenyl)phenyl]-N-cyclohexylcarbamate
- URB-602; Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate
- URB-754; 6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one
- URB-937; 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl cyclohexylcarbamate
- Viminol; 1-[1-(2-chlorobenzyl)-1H-pyrrol-2-yl]-2-(di-sec-butylamino) ethanol
- W-15; (E)-4-chloro-N-(1-phenethylpiperidin-2-ylidene)benzenesulfonamide
- WIN 48,098, Pravadoline; (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone; OR (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone
- WIN 55,212-2; (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone; OR [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone

## 8.0 Exemptions

**8.1** Paregoric (camphorated opium tincture) is specifically exempted from this regulation.

**8.2** The following substances when labeled and in the form and quantity listed in the following section of 21 Code of Federal Regulation, Chapter II, Part 1308, dated April 1, 1976 and the Federal Register are hereby exempted from this regulation:

- 21 CFR 1308.22
- 21 CFR 1308.24(i)
- 21 CFR 1308.32(b)
- 41 FR 14190 & 14189

- 41 FR 16552 – 16553
- 41 FR 21346
- 41 FR 28515 – 28516
- 41 FR 14189 – 14190
- 41 FR 16552 – 16553
- 41 FR 28515 – 28516

## 9.0 Dosages and Doses

9.1 The benchmarks found in this section are for the sole purpose set forth under 18 V.S.A. § 4234 to provide prosecutors the ability to seek enhanced penalties based on the amount of the controlled substance(s) found unlawfully in a person's possession. These benchmarks are not therapeutic limits and do not establish a standard of practice.

### 9.2 Benchmark Unlawful Dosage

The following benchmark unlawful dosages are established for the drugs named:

<u>Drug</u>	<u>Dosage</u>
▪ Hydrocodone	45mg
▪ Codeine	360mg
▪ Hydromorphone	24mg
▪ Alprazolam	4mg
▪ Methylphenidate	60mg
▪ Methadone	80mg
▪ Phenobarbital	260mg
▪ Chlordiazepoxide	100mg
▪ Butalbital	300mg
▪ Phentermine	37.5mg
▪ Flurazepam	30mg

▪ Pentobarbital	80mg
▪ Oxycodone	20mg
▪ Propoxyphene	390mg
▪ Morphine	180mg
▪ Chlorazepate	90mg
▪ Secobarbital	100mg
▪ Amylbarbital	100mg
▪ Phenmetrazine	75mg
▪ Lorazepam	10mg
▪ Meperidine (Pethidine)	600mg
▪ Pentazocine	100mg
▪ Dihydrocodeinone	20mg
▪ Temazepam	30mg
▪ Triazolam	0.5mg
▪ Opium extracts	240mg
▪ Tincture of opium	120mg
▪ Methamphetamine	25mg
▪ Phencyclidine	10mg
▪ Amphetamine	30mg
▪ Methaqualone (Qualludes)	500mg
▪ Methaqualone Hydrochloride (Parest)	500mg
▪ Diazepam (Valium)	40mg
▪ Diethylpropione (Tenuate, Tepanil)	75mg